587 related articles for article (PubMed ID: 23510069)
1. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
2. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
3. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.
Lu Z; Wang J; Zheng Y; Yang S; Liu M; Chen X; Wang C; Hou G
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26725440
[TBL] [Abstract][Full Text] [Related]
4. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
5. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
[TBL] [Abstract][Full Text] [Related]
6. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
8. MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.
Guanen Q; Junjie S; Baolin W; Chaoyang W; Yajuan Y; Jing L; Junpeng L; Gaili N; Zhongping W; Jun W
Biomed Pharmacother; 2018 Sep; 105():350-361. PubMed ID: 29864623
[TBL] [Abstract][Full Text] [Related]
9. HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo.
Xi R; Pan S; Chen X; Hui B; Zhang L; Fu S; Li X; Zhang X; Gong T; Guo J; Zhang X; Che S
Oncotarget; 2016 Aug; 7(35):57050-57065. PubMed ID: 27489353
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.
Yu VZ; Wong VC; Dai W; Ko JM; Lam AK; Chan KW; Samant RS; Lung HL; Shuen WH; Law S; Chan YP; Lee NP; Tong DK; Law TT; Lee VH; Lung ML
Gastroenterology; 2015 Dec; 149(7):1825-1836.e5. PubMed ID: 26302489
[TBL] [Abstract][Full Text] [Related]
11. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
Harada K; Miyake H; Kumano M; Fujisawa M
Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
[TBL] [Abstract][Full Text] [Related]
13. Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway.
Fujikawa M; Koma YI; Hosono M; Urakawa N; Tanigawa K; Shimizu M; Kodama T; Sakamoto H; Nishio M; Shigeoka M; Kakeji Y; Yokozaki H
Am J Pathol; 2021 Apr; 191(4):686-703. PubMed ID: 33460563
[TBL] [Abstract][Full Text] [Related]
14. BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway.
Yang XX; Ma M; Sang MX; Zhang XY; Liu ZK; Song H; Zhu SC
Oncol Rep; 2018 Feb; 39(2):667-678. PubMed ID: 29207170
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma
Hu DX; Sun QF; Xu L; Lu HD; Zhang F; Li ZM; Zhang MY
World J Gastroenterol; 2022 Jan; 28(4):464-478. PubMed ID: 35125830
[TBL] [Abstract][Full Text] [Related]
16. Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice.
Rho O; Kiguchi K; Jiang G; DiGiovanni J
Mol Carcinog; 2014 Nov; 53(11):871-82. PubMed ID: 24114993
[TBL] [Abstract][Full Text] [Related]
17. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
[TBL] [Abstract][Full Text] [Related]
18. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Li B; Tsao SW; Li YY; Wang X; Ling MT; Wong YC; He QY; Cheung AL
Int J Cancer; 2009 Dec; 125(11):2576-85. PubMed ID: 19551863
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
